SkyCell raises USD 57 million to revolutionize pharmaceutical logistics

01.11.2023 13:00, Rita Longobardi

The company plans to utilize the funds to enhance its worldwide presence, building upon a continuous period of business growth, which has seen a compounded growth rate of over 55% in the past three years.

Catalyst, a part of M&G Investments' purpose-led private assets strategy with a whopping USD 6 billion backing, has invested in SkyCell, a forward-thinking technology company led by CEO Richard Ettl. SkyCell is revolutionizing the pharmaceutical supply chain by leveraging a blend of innovative software, hardware, and big data. Their Hybrid container concept tackles the pressing global issue of safe medicine access by offering door-to-door solutions that shield pharmaceuticals from extreme temperature variations, spanning from a bone-chilling -30°C to a scorching +70°C. This proactive approach significantly reduces the pharmaceutical industry's losses resulting from temperature excursions.

SkyCell underscores the enormity of the issue they tackle: a staggering USD 35 billion worth of pharmaceutical products are lost each year due to temperature fluctuations in the supply chain. The Swiss-made containers from SkyCell exhibit an exceptional track record, boasting a failure rate of under 0.1%, a stark contrast to the industry's usual rate of 2-12%. Furthermore, these containers don't just offer reliability; they're also environmentally conscious. Their lightweight design and increased payload efficiency lead to a significant reduction in CO2 emissions by up to 50%, providing a sustainable solution to address the pharmaceutical industry's 4.4% contribution to global emissions.

SkyCell was ranked among the TOP 100 Scale-ups in 2021 and 2022.


SkyCell Co-founders: Nico Ros and Richard Ettl